Farmas USA

NVAX

Jajaja, pues tiene la puerta abierta de par en par.

Han movido de un volumen de 10,8 M unos 4 M al final de sesión, para bajarla de esos 8,73 $ que tan buenos eran.

Amarin beats by $0.02, misses on revenue

Amarin (NASDAQ:AMRN): Q4 EPS of -$0.11 beats by $0.02.
Revenue of $16.5M (+63.2% Y/Y) misses by $0.9M.

http://seekingalpha.com/pr/12712726-amarin-reports-fourth-quarter-and-year-end-2014-financial-results-and-provides-update-on-operations?app=n

AMRN

De momento cierta euforia retail en AH a la espera de la CC.

Ayer decía que había que estar por debajo de -0,14 EPS, así que -0,11 es muy bueno. Esos ingresos de menos puede que sea por cierto estancamiento en las ventas.

AMRN

http://www.bolsamadrid.es/docs/Inversores/Guias/esp/Fichas/Fichas_%20Opas%20que%20son%20como%20actuar.pdf

Hasta los 1,64$ q ha tocado la jo día
AMRN

pero que ha sido esooooo!!
4 millones de cromos en el cierre de NVAX??
que bestiaaaa algunooooo!

NVAX

Gracias kubbatta:

• Amarin (NASDAQ:AMRN) Q4 results ($M): Revenues: 16.5 (+63.5%); Operating Expenses: 30.8 (-20.8%); Net Loss: (19.7) (-27.6%); Loss Per Share: (0.11) (+59.3%); Quick Assets: 119.5 (-37.6%).
• Vascepa revenue of $16.5M represented a sequential increase of 17.0% versus Q3. Prescriptions were up 11% sequentially and 55% compared to a year ago.
• Patient enrollment in the REDUCE-IT cardiovascular outcomes trial should be completed this year (8,000 subjects). The study will continue until the attainment of 100% of the 1,612 primary endpoint events which is estimated to happen in 2017 with results ready for publishing in 2018.
• The company does not expect a favorable decision from the FDA regarding its ANCHOR supplemental New Drug Application (sNDA) which had a PDUFA date of December 20, 2013. In September 2014, the agency denied the company's appeal of its decision to rescind the ANCHOR trial Special Protocol Assessment (SPA) and management decided not to appeal further.

AMRN